


Oslo, 27 April 2016: Photocure ASA (OSE: PHO).

Reference is made to the stock exchange release disclosed 26 April 2016,
regarding proxies received by Bente-Lill Bjerkelund Romøren in connection with
the annual general meeting of PHO on 28 April 2016 (the "AGM").

Bente-Lill Bjerkelund Romøren has as chairperson of the board of directors of
PHO received additional proxies to vote for 2,213,155 shares. In total, Romøren
has received proxies to vote for 3,501,405 shares at the AGM, representing
approx. 16 % of the total shares and votes at the AGM. The proxies received are
only valid for the AGM and will lapse thereafter.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no

About Photocure ASA
Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical
company and world leader in photodynamic technology.  Based on our unique
propriety Photocure Technology® platform, Photocure develops and commercializes
highly selective and effective solutions in disease areas with high unmet
medical needs such as bladder cancer, HPV and precancerous cervical lesions and
skin conditions.  Our aim is to provide solutions that can improve health
outcomes for patients worldwide.  Photocure is listed on the stock exchange
(OSE: PHO).  Information about Photocure is available at www.photocure.com.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.



[HUG#2007236] 
    